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1. Introduction 
The literature on cancer, of the Children Hospital "JM de los Ríos", allowed us to distinguish 
two series of solid tumors in children. The first serie (1, 2, 3), from 1937 to 1976, with 581 
cases of malignant solid  tumors, 75 of which were sarcomas (Table N° 1) and a second serie 
(4, 5), from 1985 to 2001, with 1.796 cases of solid tumors, with 280 cases of soft tissue 
tumors (Table N° 2). In both series, soft tissue tumors ranked the third in frequency with the 
12.90% and 15.96% of cases, respectively. We refer to these statistics, since they are the base 
of our discussion. 
 
 1937-1962 (1) 1963-1971 (2) 1972-1976 (3) 1937-1976 
Lymphoma / 
Hodgkin 
41(13) 104(21) 39(12) 184(46) (31.66%) 
Central nervous 
system tumors 
20 56 19 95 (16.35%) 
Wilms’ tumor. 35 40 11 86 (14.80%) 
Sarcomas 
27 (soft tissue 
sarcomas 20, 
osteosarcomas 
7),
(fibrosarcomas 
of soft tissue 6, 
bone 
fibrosarcomas 2)
30
18 (soft tissue 
sarcomas 12, 
osteosarcomas 6)
75 (12.90%) 
Neuroblastoma  10 21 12 43 (7.40%) 
Bone tumors  
Retinoblastoma 16 19 2 37 (6.36%) 
www.intechopen.com
 Soft Tissue Tumors 
 
104 
Teratomas 17 11 12 40 (6.88%) 
Carcinoma 8 10 2 20 (3.44%) 
Ovarian 
dysgerminoma 
1 1 (0.17%) 
Liver tumors  
Other tumors  
Total 174 291 116 581 
Table 1. Solid tumors in the Children´s Hospital "JM de los Ríos" 1937-1976 (1, 2, 3) 
 
 1985-1995 (4) 1996-2001 1985-2001 (5) 
Lymphoma / Hodgkin 304/135 86/7 390/142 (21.71%) 
Central nervous system tumors 199 189 388 (21.60%) 
Renal Tumors  
/ Wilms’ tumor. 
115/98 80/71 195/169 (10.85%) 
Soft tissue tumors 
/Rhabdomyosarcomas 
178/114 102/54 280/168 (15.59%) 
Neuroblastoma 79 62 141 (7.85%) 
Bone tumors 58 67 125 (6.95%) 
Retinoblastoma 35 19 54 (3.00%) 
Germ cell tumors Germ 111 16 127 (7.07%) 
Carcinoma 31 15 46 (2.56%) 
Ovarian dysgerminoma    
Liver tumors 25 18 43 (2.39%) 
Other tumors 12 -5 7 (0.38%) 
Total 1147 649 1796 
Table 2. Solid tumors in the Children´s Hospital "JM de los Ríos" 1985-2001 
1.1 Incidence 
Solid tumors are approximately the 70% of cases of cancer in the children, and the other 30% 
are leukemias. In the group of solid tumors, soft tissue tumors rank third in frequency with 
15.59%, only surpassed by lymphomas 21.71% and central nervous system tumors 21.60% 
(5) Table N° 2. 
Incidence of soft tissue tumors in children and adolescents is not uniform across all ages. It 
is greater in children younger than 10 years with 73.92% and, children less of 5 years old, 
account for nearly half (48.57%) the cases  of soft tissue tumors (Table N° 3). 
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Age groups Porcentaje 
Under 1 year of age 27 (9.64%) 
1 to 4 years 109 (38.92%) 
5 to 9 years 71 (25.35%) 
10 to 15 years 69 (24.64%) 
16 to 18 years 4 (1.42%) 
Table 3. Soft tissue tumors. Distribution by age groups. Children’s Hospital “J.M. de los 
Ríos” 1985-2001 (5) 
1.2 Definition 
Soft tissue have been defined as nonepithelial extraskeletal tissue of the body, exclusive the 
reticuloendothelial system, glia and supporting tissue of various parenchymal organs (6); it 
is represented by voluntary muscle, fat, fibrous tissue and vessels serving these tissues. The 
soft tissue tumors are a heterogeneous group of tumors that derived from embryonic 
mesenchymal cells; they  are histopathológically classified, according to adult tissue that 
resembles, and may be benign or malignant. Malignant soft tissue tumors are called 
sarcomas, and there are three main groups: - rhabdomyosarcoma, - non-rhabdomyosarcoma 
soft tissue sarcoma, and - Ewing’s sarcoma. 
2. Rhadomyosarcoma (RMS) 
2.1 Definition e incidence 
Rhabdomyosarcoma is the most common malignant soft tissue tumor in childhood and 
adolescense; and represents 60% of cases  in under 18 years of age. It is originate from 
embryonic mesenchymal cells, with potential to differentiate into skeletal muscle cells, and 
is characterized by a tendency to exhibit histologic and molecular features of skeletal 
myogenesis. These tumors may arise anywhere in the body, even in sites where skeletal 
muscle is not normally found (7), and at diagnosis, the more frequent location of the tumor 
was: head and neck, genitourinary and limbs (8). 
2.2 Age distribution 
The incidence of rhabdomyosarcoma in childhood and adolescence is 60%, and is higher in 
the first decade of life with 82.73%. Approximately, 50 percent of the cases of 
rhabdomyosarcoma (48.80%) are diagnosed in children under 5 years old (1-4 years old) (5), 
and, represent 75% of soft tissue tumors in this age group tumors. (Table No. 4). 
 
Age groups  soft tissue tumors Rhabdomyosarcomas 
Under 1 year of age 27 12 (44.44%) 
1 to 4 years 109 82 (75.22%) 
 5 to 9 years 71 45 (63.38%) 
 10 to 15 years 69 27 (39.13%) 
 16 to 18 years 4 2 (50%) 
Total 280 168 (60%) 
Table 4. Relation rhabdomyosarcoma/soft tissue tumor. Distribution by age groups. 
Children’s Hospital “J.M. de los Ríos” 1985-2001 (5) 
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2.3 Histopathologic classification 
According to the histopathological and prognosis features, the rhadomyosarcomas are 
classified in the following varieties (8). Table N°5: 
 
Histopathologic varieties  Prognosis 
Botryoid embryonal rhabdomyosarcoma 
Spindle cell rhabdomyosarcoma  
Superior prognosis 
Embryonal rhabdomyosarcoma Intermediate prognosis 
Alveolar rhabdomyosarcoma 
Undifferentiated sarcoma 
Rhabdomyosarcoma with diffuse anaplasia 
Poor prognosis 
Table 5. International Prognostic Classification of Pediatric Rhabdomyosarcoma 
The incidence of the different varieties of rhabdomyosarcoma, in descending order, is the 
following (9): Embryonic (64%), Alveolar (21%), undifferenciated (8%), botryoides (6%), 
pleomorphic (1%). 
2.4 Etiology, pathogenesis and cytogenetics 
Most rhabdomyosarcomas occur sporadically without predisposing factors, and only one 
third of patients have recognizable genetic anomalies (7, 9). The cause of the 
rhabdomyosarcomas remains unknown; but  now  we know, that certain genetic alterations 
are associated with the development of this tumor. Alveolar RMS has a characteristic 
translocation between the long arm of chromosome 2 and the long arm of chromosome 13. 
This translocation has been cloned molecularly, and shown to involve the juxtaposition of 
the PAX3 gene, which thought to regulate transcription during early neuromuscular 
development (7). The embryonal rhabdomyosarcoma, has loss of heterozygosity (LOH) at 
the 11p15 locus (10). 
The Li-Fraumeni syndrome, a well-defined family cancer,  that includes rhabdomyosarcoma 
and other soft tissue sarcomas has been associated with germline mutations of the p53 gene. 
Rhabdomyosarcoma has been observed in association with Beckwith-Wiedemann  
syndrome, a fetal overgrowth syndrome associated with abnormalities on 11p15. 
The history of cancer in the family is an important, reported in 45.76% of cases. (11). 
2.5 Histopathological varieties 
There are 4 types of rhabdomyosarcoma in children, clearly defined by Imbach (9), which 
we reproduce it textually. 
2.5.1 Embryonal 
- Frequency: 53–64% of all rhabdomyosarcomas in childhood 
- Location: orbit, head and neck, abdomen, genitourinary tract 
- Microscopically resemblance to embryonic muscle tissue; mainly primitive round cells, 
some spindle cells with central nucleus and eosinophilic cytoplasm; cross striations 
characteristic of skeletal muscle in about 30% of cases. 
- Subtype: Sarcoma botryoides (6% of all rhabdomyosarcomas in children); in vagina, 
bladder, uterus; microscopically as embryonal type with polypoid mass and presence of 
a dense subepithelial cell layer. 
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- Subtype Spindle cell rhabdomyosarcoma, is a variety of embryonal 
rhabdomyosarcoma composed of tight bundles of spindle cells and resembling smooth 
muscle and fibrous neoplasms (8). It is usually located paratesticular or head and neck, 
and is difficult to differentiate from congenital fibrosarcoma. Compared to other 
rhabdomyosarcomas, this has a good prognosis. (spindle cell subtype does not appear 
in the classification of Imbach (9), so we add it) 
2.5.2 Alveolar 
- Frequency: 21% of all rhabdomyosarcomas in children 
- Location: mainly extremities 
- Histology: round cells with eosinophilic cytoplasm, occasionally with vacuoles; 
multinucleated giant cells; rarely cross-striations; groups of tumor cells separated by 
fibrotic septation (alveolar structure) 
2.5.3 Pleomorphic 
- Frequency: 1% of all rhabdomyosarcoma in children 
- Occurrence: mainly in adulthood 
- Histology: undifferentiated muscle tissue; spindle cells with variable eosinophilic 
cytoplasm and pleomorphic nuclei, frequently mitotic cells, often cross-striations, 
structured in rows and bundles. 
2.5.4 Undifferentiated subtype 
- Frequency: 8% without muscle-specific gene proteins. 
The histopathological types found in order of decreasing frequency, in Children's Hospital 
"J.M. de los Ríos", are shown in Table N°6 (10):  
 
histopathological types number of cases (%) 
Embryonal rhabdomyosarcoma 39 (66.10%) 
Embryonal rhabdomyosarcoma botryoides 
subtype 
6 (10.16%) 
Embryonal rhabdomyosarcoma spindle 
cell subtype 
1 (1.69%) 
Alveolar rhabdomyosarcoma 11 (18.64%) 
Non typeable 2 (3.38%) 
Total 59 (100%) 
Table 6. Rhabdomyosarcoma, Rhabdomyosarcoma histopathological types, Children’s 
Hospital “J.M. de los Ríos” 1997-2005 (10) 
The histologic variants embryonal and alveolar are the two more common. 
2.6 Location 
The most common sites of primary tumor are: head and neck,  including the orbit; 
genitourinary tract including the prostate, testis, vulva, cérvix and uterus; and 
extremities. (Table N° 7); and less frequent are: trunk, retroperitoneum, perianal and anal 
(7, 9, 10, 12).  
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Location number of cases (%) 
Head and neck 20 (33.89%) 
Genitourinary 14 (23.72%) 
Extremities 13 (22.03%) 
Pelvic floor 7 (11.86%) 
Trunk 4 (6.77%) 
Perianal and anal 1 (1.69%) 
Table 7. Rhabdomyosarcoma, Location of primary tumor, Children’s Hospital “J.M. de los 
Ríos” 1997-2005 (10) 
The age and location of the tumor are associated with histological varieties certain of 
rhabdomyosarcoma. Head and neck tumors are more common in children younger than 
eight years of age and when arising in the orbit are almost always of the embryonal variety, 
while extremity tumors are more common in adolescents and are typically of the alveolar 
subtype. The variant botryoides of bladder or vagina, occurs almost exclusively in infants 
(7).  
2.7 Clinical presentation 
The clinical manifestations of rhabdomyosarcoma depends on the age at diagnosis, location 
of primary tumor,  and the presence or absence of metastasis. 
2.7.1 Head and neck 
The primary tumor is usually located in: orbit, head and neck superficial, and 
parameningeal. Clinical symptoms will depend on the location of the tumor and usually 
present with a painless, enlarging mass that can obstruct a sinus, grow into the nasal cavity, 
cause proptosis, or simulate chronic otitis media (12) and clinical symptoms include nasal 
discharge or obstruction of the airways, otorrhea,  and rapid proptosis. The more deep-
seated tumors, signs and symptoms may result from compression of nerves, blocked 
vessels, or both;  cranial nerve palsy or other neurological deficits indicates the extent of the 
tumor at the base of the skull or the central nervous system. (13). The parameningeal 
localization is the most frequent and a poorer prognosis; usually located in pterygoid 
infratemporal fossa, nasopharyngeal cavity, paranasal sinuses and middle ear and mastoid, 
and these four locations include the 91.52% of cases (14).  
2.7.2 Genitourinary tract 
The embryonal type is the commonest in this región, and arise in the bladder, prostate, 
vagina, uterus, vulva, paratesticular regions. Children with bladder rhadomyosarcoma are 
usually under 4 years of age, and may present with hematuria, urinary obstruction and 
rarely extrusion of tumor tissue. The bladder tumors usually grow intra-luminally, in the 
region of the trigone and have a polypoidal appearance on gross or endoscopic examination. 
Prostatic tumors can occur in relatively older children and usually present as large pelvic 
masses with or without urethral strangury and/ or constipation. Within the category of 
genitourinary rhabdomyosarcoma, tumors located in the vulva, vagina and paratesticular 
are a good prognosis; whereas those located in the bladder and prostate have the worst 
prognosis. 
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2.7.3 Extremities 
Rhabdomyosarcomas are located in the extremities present clinically as painless masses. 
As soon as the suspected tumor, this diagnosis should be confirmed through an MRI, and to 
establish the histopathological diagnosis of the lesion should be performed an open biopsy, 
or with needle. If frozen sections suggest that the lesion is malignant, tissue samples must be 
sent for chromosome analysis. 
2.8 Staging classification, treatment and prognosis 
To plan appropriate treatment, it is necessary to determine the degree of progression of the 
disease. The clinical classification grouping (15), classifies the extent of the disease into four 
groups.  
IRS clinical grouping classification (stage) 
Group I: Localized disease, completely resected, no microscopic residual 
Regional nodes not involved—lymph node biopsy or dissection is required except for head 
and neck lesions 
A. Confined to muscle or organ of origin, completed resected 
B. Infiltrating beyond site of origin, completely resected 
Notation: This includes both gross inspection and microscopic confirmation of complete 
resection. Any nodes that may be inadvertently taken with the specimen must be negative. 
If the latter should be involved microscopically, then the patient is placed in group IIB or 
group IIC (see below). 
Group II: Total gross resection with evidence of regional spread, completely resected 
A. Grossly resected tumor with microscopic residual disease  
Surgeon believes that all the tumor has been removed, but the pathologist finds tumor at the 
margin of resection, and additional resection to achieve a clean margin is not feasible. No 
evidence of gross residual tumor; no evidence of regional node involvement; once 
radiotherapy and/or chemotherapy have been started, re-exploration and removal of the 
area of microscopic residual does not change the patient’s group. 
B. Regional disease with involved nodes, completely resected with no microscopic 
residual 
Notation: Complete resection with microscopic confirmation of no residual disease makes 
this different from group IIA and group IIC. Additionally, in contrast to group IIA, regional 
nodes (which are completely resected, however) are involved, but the most distal node is 
histologically negative. 
C. Regional disease with involved nodes, grossly resected, but with evidence of 
microscopic residual and/or histologic involvement of the most distal regional node 
(from the primary site) in the dissection 
Notation: The presence of microscopic residual disease makes this group different from 
group IIB, and nodal involvement makes this group different from group IIA. 
Group III: Incomplete resection with gross residual disease 
A. After biopsy only 
B. After gross or major resection of the primary (>50%) 
Group IV: Distant metastatic disease present at onset 
Lung, liver, bones, bone marrow, brain, and distant muscle and nodes. 
Notation: The above excludes regional nodes and adjacent organ infiltration, which places 
the patient in a more favorablegrouping (as noted above under group II). 
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The presence of positive cytology in the cerebrospinal fluid, pleural or abdominal fluids, as 
well as implants on pleural or peritoneal surfaces are regarded as indications for placing the 
patient in group IV. 
The size of the primary tumor is a prognostic factor. Tumors less than or equal to 5 cm are 
classified in the subgroup a, and tumors larger than 5 cm are classified in subgroup b (16). 
However, this tumor size has a different meaning according to the body surface. A tumor of 
5 cm in a children or an adolescent have not the same meaning  a 5 cm tumor in a neonate or 
an infant, what is proposed, relating the size of the primary tumor with the patient's body 
surface (17).  
Rhabdomyosarcoma is a systemic disease, with high probability of spread to lymph nodes, 
bone marrow, bone, soft tissue distance, and pleural or peritoneal spaces adjacent to the 
primary site; and have propensity to spread to the lung parenchyma. Therefore, the diagnostic 
study to determine the extent of the disease includes: obtaining a chest radiograph and lateral, 
computed tomography (CT) scan of the chest, bone marrow aspiration, biopsy, total body 
bone scan and cerebrospinal fluid samples from patients with orbital tumors parameningeal or 
other (eg, tumors of the nasopharynx, paranasal sinuses, pterygoid fossa / infratemporal, and 
the region middle-ear/mastoid). Patients with rhabdomyosarcomas are classified on the basis 
de their  low, intermediate, or high risk for treatment failure (18). Treatment is then tailored to 
the appropriate risk level. It is standard practice to repeat imaging studies at 2- to 4-month 
intervals during and after therapy and to obtain blood samples and chemistries before each 
course of multiple-agent chemotherapy. (12). 
At the present time, more than 70% of children and adolescents with rhabdomyosarcoma 
are cured with combined modality treatment (chemotherapy, radiation and surgery) (19), 
but the results will be different depending on the clinical group,  histological type, anatomic 
location and age at presentation of disease, factors that determine the prognosis of the 
disease and levels of risk of treatment failure. 
 The low-risk patients are those with rhabdomyosarcomas of the embryonal variety, in any 
anatomical location, which have been surgically resected (stages 1-3), or irresectables but 
in favorable anatomical sites. Favorable anatomic locations are considered 
nonparameningeal head and neck sites (oropharynx, scalp, parotid, neck, larynx, cheeks, 
eyelids, hypopharynx), and genitourinary system excluding the bladder and prostate. 
Their survival rate is over 90% when treated with vincristine and dactinomycin or 
vincristine, dactinomycin and cyclophosphamide with or without radiotherapy.  
 The intermédiate-risk patients are those with unresectable tumors of the embrional 
variety, in unfavorable locations, ó that are metastatic at the time of diagnosis in 
patients younger than 10 years old; and all those with non metastatic 
rhabdomyosarcomas of the alveolar variety. The survival of this group is about 50%-
75% and investigated the effectiveness of new drugs such as topotecan. 
Rhabdomyosarcomas of the alveolar variety, stages I-III, require complementary 
treatment with radiotherapy 
 The high-risk patients  are those with metastatic at the time of diagnosis and the 
survival of this group is only 25% 
3. Nonrhabdomyosarcomas soft tissue tumors  
3.1 Definition e incidence 
Nonrhabdomyosarcomas soft tissue tumors are a heterogeneous group of mesenchymal cell 
neoplasms, most of which are typified with the named for the mature tissue that the tumor 
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most resembles and represent 4.23% of solid tumors (5) and 27.14% of soft tissue tumors in 
patients under 18 years Fig Nº 1 
 
 
 
 
 
 
Fig. 1. Soft tissue tumors 280 cases, Children Hospital "JM de los Rios" 1985-2001. 
There are differences in soft tissue sarcomas in children and adults in terms of histological 
types and frequency; differences which have therapeutic implications (20). In Children are 
more frequent the malignant tumors of the peripheral nerve sheath and fibrosarcoma (5), 
while adults are more frequent Kaposi's sarcoma, leiomyosarcoma and malignant fibrous 
histiocytoma (20).  
3.2 Age distribution 
The distribution of the different varieties of norhabdomyosarcomas soft tissue tumors varies 
with age; myofibromas and fibrosarcoma  are more common in infants, whereas the 
synovial sarcoma and malignant peripheral nerve sheath tumor is more common in older 
children and adolescents (12). It is necessary to highlight the characteristics of soft tissue 
tumors in the first year of life. Approximately 20% of soft tissue tumors that occur in 
children under 20 years are presented in the first year of age, and of these just over half 
presented in the first three months of life. 85% of soft tissue tumors present in the first year 
of life are classified as benign or borderline lesions and the remaining 15% are malignant. 
The benign and borderline lesions most common are: infantile hemangioendothelioma, 
lymphangiomas, myofibromas, fibrous histiocytoma, and congenital or infantile 
fibrosarcoma and represent 68.71% of this group, while embryonal rhabdomyosarcoma and 
primitive neuroectodermal tumor are the most common malignant lesions, and represent for 
62.96% of this group (21). 
3.3 Histopathologic classification 
Soft tissue tumors are grouped  for classification according to cell type that most resembles. 
Table Nº 8. 
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Cell Type Benign Tumor Malignant Tumor 
Fibroblast, including 
myofibroblast 
Fibroma, myxoma Fibrosarcoma, malignant 
fibrous histiocytoma 
Adipocyte Lipoma Liposarcoma 
Smooth muscle cell Leiomyoma Leiomyosarcoma 
Skeletal muscle cell Rhabdomyoma Rhabdomyosarcoma 
Endothelial cell Hemangioma Angiosarocoma, Kaposi 
sarcoma 
Schwann cell Schwannoma, 
neurofibroma 
Some malignant peripheral 
nerve sheath tumors 
Cartilage cell Chondroma Chondrosarcoma 
Interstitial cell of Cajal of 
intestines 
 Gastrointestinal stromal 
tumors, a spectrum from 
benign to malignant 
Histiocyte Juvenile xanthogranuloma 
Rosai-Dorfman disease? 
Histiocytic sarcoma  
(True histiocytic lymphoma) 
Lymphoid cells Benign lymphoid 
hyperplasia 
Extranodal lymphomas in 
soft tissues 
No known normal cell or 
benign counterparts 
 Ewing family tumors 
Synovial sarcoma 
Epithelioid sarcoma 
Alveolar soft  
part sarcoma 
aIntermediate categories between benign and malignant tumors are excluded for simplicity. 
Table 8. Simplified Chart of the Major Types of Primary Soft Tissue Tumors Grouped 
According to the Cell Types that They Resemblea  (22) 
3.4 Etiology, pathogenesis and cytogenetics 
The cause of the soft tissue sarcomas remains unknown, but  in nonrhabdomyosarcomas 
soft tissue tumors have identified genetic alterations. In the fibrosarcoma, a characteristic 
translocation t (12; 15) (p13; q25) with an ETV6-NTRK3 gene fusion, and gains of 
chromosomes 8, 11, 17 and 20 (23).  Synovial sarcoma has and a specific chromosomal 
translocation t(X;18)(p11;q11) (23).  
3.5 Location 
The anatomical location of primary tumor in descending order of frequency is: head and 
neck, trunk and extremities. However this varies depending on the histologic type of tumor. 
The most frequent  primary tumor site was: in fibrosarcoma, the limbs in 66% (24); in 
myofibromas, head, neck, and trunk in 69%  (25); in sinovial sarcoma,  the limbs nears joints 
and tendons in the 77.96% (26).  
3.6 Clinical presentation 
The most common clinical presentation is a painless mass, although the involvement of 
adjacent structures can cause pain and other symptoms (27) 
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3.7 Staging classification, treatment and prognosis 
Non rhabdomiosarcomas soft tissue tumors can be benign or malignant and malignant are 
called sarcomas. The histopathologic features determine the prognosis and treatment follow 
(28, 29) and hence the classification of degrees. Table Nº 9  
 
Grade 1 
 
Myxoid and well-differentiated liposarcoma 
Well-differentiated or infantile (≤4 years old) fibrosarcoma 
Well-differentiated or infantile (≤4 years old) hemangiopericytoma 
Well-differentiated malignant peripheral nerve sheath tumor 
Angiomatoid malignant fibrous histiocytomab 
Deep-seated dermatofibrosarcoma protuberans 
Myxoid chondrosarcoma 
Grade 2 
 
≤15% of the surface area shows necrosis 
The mitotic count is <5 mitotic figures per 10 high-power fields using a 340 objective 
Nuclear atypia is not marked 
The tumor is not markedly cellular 
Grade 3 
 
Pleomorphic or round-cell liposarcoma 
Mesenchymal chondrosarcoma 
Extraskeletal osteogenic sarcoma 
Malignant triton tumor 
Alveolar soft part sarcoma 
Any other sarcoma not in grade 1 with >15% necrosis and/or ‡5 mitotic figures per10 
high-power fields using a 340 objective 
Table 9. The Pediatric Oncology Group Grading System for Nonrhabdomyosarcomatous 
Soft Tissue Sarcomas of Children  
The proper classification of non rhabdomyosarcomas soft tissue tumors is not easy and 
raises diagnostic problems that require additional methods such as immunohistochemistry, 
genetic studies, and consultation by experts (30). Myofibromas are benign lesions with 
difficulty diagnostic because they may be mistaken for malign lesions with 
hemangiopericytoma-like findings (31). 
The evalucación diagnosed, requires magnetic resonance imaging and computed 
tomography to determine the extent of the disease and a plan for surgery (32).  
Treatment and prognosis depends on the extent of disease and histological type of injury, 
poor prognostic factors are:  high histologic grade, intra-abdominal primary tumor, and 
microscopic residual disease after initial resection (32, 33). Radiation therapy is useful in 
tumors whose location does not allow excision and all tumors larger than 5 cm. or that could 
not be completely resected. Sarcomas in children are more sensitive to chemotherapy report 
answer 40 to 60% using multiple drugs, hence its use in all tumors larger than 5 cm, of axial 
location, with histological  high grade, or with metastatic disease. 
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